EULAR® 2024 Insights

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

EULAR® 2024 Insights

Rheumatoid Arthritis
SLE
Osteoarthritis
Spondyloarthropathies
Crystal Arthropathies
Osteoporosis
Systemic and Connective Tissue Disease
Vasculitis
All Rheumatology

EULAR® 2024 Insights- Implications of Newly Established Malignancy Screening Guidelines for Idiopathic Inflammatory Myopathies: A Multicentre, International Evaluation of Clinical and Economic Impact by the Myositis Audit and Research Collaborative Group

By EULAR® 2024 Insights FEATURING Jessica Day

14 views

July 24, 2024

Comments 0

Systemic and Connective Tissue Disease

EULAR® 2024 Insights- Implications of Newly Established Malignancy S…

EULAR® 2024 Insights

J. Day

161 views

EULAR® 2024 Insights- Implications of Newly Established Malignancy S…

EULAR® 2024 Insights

J. Day

14 views

EULAR® 2024 Insights: Implications of Newly Established Malignancy S…

EULAR® 2024 Insights

J. Day

Inflammatory Myopathies - Update on Therapies

EULAR® 2024 Insights

B. Maurer

440 views

Sarcoidosis – (Not Just) Joint, Bone, and Muscles

EULAR® 2024 Insights

A. Yee

536 views

EULAR ® Insights - The Most Reliable Tools and Methods and Their Com…

EULAR® 2024 Insights

A. Herrick

82 views

EULAR® 2024 Insights: The Effects of Immunosupressive Therapy on Gla…

EULAR® 2024 Insights

G. Inanc

354 views

EULAR® 2024 Insights - Predictive Significance of Biomarkers in Syst…

EULAR® 2024 Insights

C. Sieiro Santos

111 views

EULAR ® Insights: The Most Reliable Tools and Methods and Their Comb…

EULAR® 2024 Insights

A. Herrick

12 views

Decoding the Immunopathophysiology of Polymyalgia Rheumatica: Unrave…

EULAR® 2024 Insights

E. Choy

116 views

EULAR® 2024 Insights: Characteristics Associated with Long-Term Gluc…

EULAR® 2024 Insights

A. Rubbert-Roth

107 views